{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:46:50Z","timestamp":1784803610015,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.lungcan.2021.06.015","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:55:51Z","timestamp":1626436551000},"page":"96-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Real-world insights into patients with advanced NSCLC and MET alterations"],"prefix":"10.1016","volume":"159","author":[{"given":"Marisa","family":"Bittoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeswara Rao","family":"Arasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Oksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Boutmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Stroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Johne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2021.06.015_b0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1535-7163.MCT-16-0472","article-title":"MET in lung cancer: Biomarker selection based on scientific rationale","volume":"16","author":"Salgia","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2021.06.015_b0010","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2021.06.015_b0015","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/JCO.2020.38.15_suppl.9511","article-title":"Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms","volume":"38","author":"Awad","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0025","doi-asserted-by":"crossref","first-page":"djw262","DOI":"10.1093\/jnci\/djw262","article-title":"Exon 14 deleted MET receptor as a new biomarker and target in cancers","volume":"109","author":"Cortot","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2021.06.015_b0030","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2016.34.15_suppl.9067","article-title":"Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Schuler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0035","doi-asserted-by":"crossref","first-page":"e107677","DOI":"10.1371\/journal.pone.0107677","article-title":"MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); A systematic review and meta-analysis","volume":"9","author":"Dimou","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.lungcan.2021.06.015_b0040","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non\u2013small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0045","unstructured":"National Comprehensive Cancer Network, Non-Small Cell Lung Cancer Version 4.2021, (2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf (accessed March 18, 2021)."},{"key":"10.1016\/j.lungcan.2021.06.015_b0050","article-title":"ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up \u2020","volume":"192\u2013237","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0060","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2020-0760","article-title":"New verse for a familiar song: Small molecule inhibitors for MET exon 14 skipping non-small cell lung cancer","volume":"25","author":"Le","year":"2020","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2021.06.015_b0065","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non\u2013small-cell lung cancer: American Society of clinical oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0070","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2021.06.015_b0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer\u2014a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0080","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0085","doi-asserted-by":"crossref","unstructured":"M.A. Pruis, W.R.R. Geurts-Giele, T.J.H. von der, I.C. Meijssen, W.N.M. Dinjens, J.G.J. V Aerts, A.M.C. Dingemans, M.P. Lolkema, M.S. Paats, H.J. Dubbink, Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer, Lung Cancer. 140 (2020) 46\u201354. Doi: 10.1016\/j.lungcan.2019.11.010.","DOI":"10.1016\/j.lungcan.2019.11.010"},{"key":"10.1016\/j.lungcan.2021.06.015_b0090","unstructured":"J. Wolf, C. Baik, R.S. Heist, J.W. Neal, A.S. Mansfield, R. Buettner, K.L. Davis, M. Giovanni, A. Mutebi, M.M. Awad, Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts), in: EORTC\/AACR\/NCI Symp., Dublin, 2018: p. PB--066."},{"key":"10.1016\/j.lungcan.2021.06.015_b0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","article-title":"Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis","volume":"133","author":"Awad","year":"2019","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2021.06.015_b0100","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","article-title":"Crizotinib in MET-deregulated or ROS1-rearranged pretreated non\u2013small cell lung cancer (METROS): A phase II, prospective, multicenter, two-arms trial","volume":"25","author":"Landi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2021.06.015_b0105","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.21873\/invivo.11920","article-title":"Characteristics and clinical outcomes of non-small cell lung cancer patients in Korea with MET exon 14 skipping","volume":"34","author":"Hur","year":"2020","journal-title":"In. Vivo."},{"key":"10.1016\/j.lungcan.2021.06.015_b0110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0115","doi-asserted-by":"crossref","unstructured":"L.H. Schwartz, S. Liti\u00e8re, E. De Vries, R. Ford, S. Gwyther, S. Mandrekar, L. Shankar, J. Bogaerts, A. Chen, J. Dancey, W. Hayes, F.S. Hodi, O.S. Hoekstra, E.P. Huang, N. Lin, Y. Liu, P. Therasse, J.D. Wolchok, L. Seymour, RECIST 1.1 - Update and clarification: From the RECIST committee, Eur. J. Cancer. 62 (2016) 132\u2013137. Doi: 10.1016\/j.ejca.2016.03.081.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"10.1016\/j.lungcan.2021.06.015_b0120","first-page":"4728","article-title":"Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1\/PD-L1 inhibitors","volume":"9","author":"Song","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2021.06.015_b0125","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0130","doi-asserted-by":"crossref","first-page":"9064","DOI":"10.1200\/JCO.2018.36.15_suppl.9064","article-title":"Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials","volume":"36","author":"Gong","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers11122033","article-title":"Clinicopathologic and imaging features of non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"11","author":"Digumarthy","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.lungcan.2021.06.015_b0140","doi-asserted-by":"crossref","unstructured":"D.R. Camidge, H.R. Kim, M.J. Ahn, J.C.H. Yang, J.Y. Han, J.S. Lee, M.J. Hochmair, J.Y.C. Li, G.C. Chang, K.H. Lee, C. Gridelli, A. Delmonte, R. Garcia Campelo, D.W. Kim, A. Bearz, F. Griesinger, A. Morabito, E. Felip, R. Califano, S. Ghosh, A. Spira, S.N. Gettinger, M. Tiseo, N. Gupta, J. Haney, D. Kerstein, S. Popat, Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer, N. Engl. J. Med. 379 (2018) 2027\u20132039. Doi: 10.1056\/NEJMoa1810171.","DOI":"10.1056\/NEJMoa1810171"},{"key":"10.1016\/j.lungcan.2021.06.015_b0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0150","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.06.015_b0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.06.015_b0160","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.06.015_b0165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.lungcan.2021.06.015_b0175","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fgene.2019.01008","article-title":"Genomic profiling of driver gene mutations in chinese patients with non-small cell lung cancer","volume":"10","author":"Meng","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.lungcan.2021.06.015_b0180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","author":"Cheng","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220670","article-title":"MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population","volume":"14","author":"Lung","year":"2019","journal-title":"PLoS One."},{"key":"10.1016\/j.lungcan.2021.06.015_b0190","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0195","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0200","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0205","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.06.015_b0210","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.06.015_b0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2021.06.015_b0220","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.2147\/OTT.S219959","article-title":"Targeting the MET-signaling pathway in non-small\u2013cell lung cancer: Evidence to date","volume":"13","author":"Bylicki","year":"2020","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.lungcan.2021.06.015_b0225","unstructured":"Center for Drug Evaluation and Research, Novartis Multi-Country Chart Review Study, (2019). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213591Orig1s000AdminCorres.pdf (accessed January 7, 2021)."},{"key":"10.1016\/j.lungcan.2021.06.015_b0230","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","article-title":"Efficacy and safety of anti\u2013PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018","volume":"15","author":"Guisier","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2021.06.015_b0235","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/jcm9051362","article-title":"Immune checkpoint inhibitors for lung cancer treatment: A review","volume":"9","author":"Onoi","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2021.06.015_b0240","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Futur. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022100458X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022100458X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:54:45Z","timestamp":1759236885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022100458X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":48,"alternative-id":["S016950022100458X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world insights into patients with advanced NSCLC and MET alterations","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}